Leflunomide is Safe and Effective for the Induction and Maintenance of Idiopathic Pulmonary Hemosiderosis Remission
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The goal of this clinical trial is to compare Leflunomide in Idiopathic pulmonary hemosiderosis. The main questions it aims to answer are: * The efficacy and safety of Leflunomide in Idiopathic pulmonary hemosiderosis * The mechanism of leflunomide in treating Idiopathic pulmonary hemosiderosis Participants will be treated with leflunomide plus stroid. A comparison group: Researchers will compare the control group treated with stroid to see if the efficacy of Leflunomide would be better than control group.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5 months
Maximum Age: 18
Healthy Volunteers: f
View:
• Age range from 6 months to 18 years old;
• Diagnose as IPH;
• Parents or guardians agree to treatment and sign a written informed consent form.
Locations
Other Locations
China
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
RECRUITING
Guangzhou
Contact Information
Primary
Haiyan Wang, MD
wanghy78@mail.sysu.edu.cn
8613560489257
Backup
Weiping Tan, PhD
tanweip@mail.sysu.edu.cn
8613556196566
Time Frame
Start Date: 2023-06-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 34
Treatments
Experimental: IPH Patients
Leflunomide+Steroid treatment
Active_comparator: Control Group
Steroid treatment
Related Therapeutic Areas
Sponsors
Leads: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University